Study design: The study was a multicentre, prospective, randomised, doubleblind, parallel-group study.
|
|
- Shanna Bryant
- 5 years ago
- Views:
Transcription
1 2 11 September Page 9 of161 SYNOPSIS FUT 9403 INT : FUCIDIN VERSUS ERYTHROMYCIN IN SKIN AND SOFT TISSUE INFECTION. A comparison of sodium fusidate tablets 250mg bd (Fucidin tablets) and erythromycin tablets l.og bd (Erythroped A tablets) in skin and soft tissue infection. Objectives: To compare the overall clinical and bacteriological effect, symptomatic response, tolerability, acceptability and cost effectiveness of Fucidin tablets with Erythroped A tablets in treating skin and soft' tissue infection. The primary criterion of response was the investigators' assessment of overall clinical response 'cured' or 'improved' after five days of treatment. Study design: The study was a multicentre, prospective, randomised, doubleblind, parallel-group study. Eligible patients were randomly assigned to receive an initial five day course of Fucidin tablets 250mg bd or Erythroped A tablets 1.0g bd and were reviewed on day 6. Patients requiring a further five day course of antibiotic were seen again on day 11. A follow-up visit was conducted 14 days after co~pletion of trea't ment. Assessments were made at days 1, 6, 11 and at the follow-up visit (day 20 or 25). Duration of study phases: The study was divided into two phases: phase I, double blind comparative treatment and phase II, follow-up. Phase I started at visit 1 (day 1) and ended at visit 2 (day?) for patients who received five days of treatment and ended at visit 3 (day 11) for patients who received ten days treatment. Phase Il, follow-up was only for patients rated as 'cured' at visit 2 or 3. Phase II started at the end of treatment (visit 2 or 3) and ended at the follow-up visit, 14 days later. Source of patients: Patients enrolled into this study were general practice or domiciliary patients. This docwnent has been downloaded from \V\vw.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formul ations or treatment regimens, and it is provided for transparency and informational purposes only. The content does not reflect the complete results from all studies related to a product. As a document of scientific nature 1t is not to be seen as a recommendation or advic-e regarding the use of any products and you must always consult the specific prescribing information approved for the product prior to any prescription or use.
2 Page 10 of 161 Patient group studied: Patients of either sex, aged 18 years or over, with skin and/ or soft tissue infection, for which oral antibacterial therapy was indicated, e.g. boil(s), carbuncle(s), superficial abscess(es), acute paronychia, impetigo, traumatic wound infection, or acute folliculitis, were included after they had given signed, informed consent. Excluded were hospitalised patients and patients who had cellulitis,. chronic/ recurrent furunculosis, post-operative wound infections, leg ulcers or deep tissue abscess(es). Also excluded were patients with known or suspected hypersensitivity to constituents of either treatment, diabetics or patients receiving immunosuppressives, digoxin, warfarin, carbamazepine, high dose theophylline or topical or systemic antibiotic therapy within the previous seven days. Study medication: Patients were randomised to either Fucidin tablets 250 mg bd or Erythroped A tablets l.og bd. Patients were instructed to take all tablets from a blister, morning and evening for five days. Tablets were to be taken with a glass of fluid either with or without food. Criteria for efficacy, safety, acceptability and cost t:ffectiveness: The two treatment groups were compared in respect of the primary efficacy criterion which was the investigators' assessment of overall clinical response 'cured' or 'improved' after five days of treatment. Secondary criteria of response included the investigators' assessment of overall clinical treatment response at end of treatment and assessment of relapse. The patients' assessment of symptomatic improvement and treatment acceptability was examined. The bacteriological response, cost effectiveness and safety were also assessed. Study procedures: Investigators' assessments at the first visit: diagnosis, duration, severity, location and signs/symptoms of the skin or soft tissue infection were recorded. At each on treatment visit the investigator recorded the overall clinical response to treatment as 'cured', 'improved' (visit 2 only), failed' or 'unevaluable'. The local signs/symptoms (overall severity of lesion, redness and oedema); spontaneous discharge (purulent and serous) were assessed. An assessment of relapse was determined at the follow-up visit.
3 Page 11 of 161 Patients' assessments: at the first visit and at each on treatment visit heat and pain were recorded. At each on treatment visit the patients' satisfaction with treatment was recorded.. Bacteriological assessments: lesion cultures were taken at baseline and at each subsequent visit where pathological material was present. Adverse events: were recorded at each post-randomisation visit. A tabulated schedule of study procedures is outlined below. Visit 1 (Day1) Informed consent Inclusion/ exclusion checklist Medical history Primary diagnosis Other concurrent diagnoses Concurrent medication Clinical assessment of lesion Stratify to 'open'/' closed' lesion group Randomisation Bacteriological assessment Dispense treabnent Overall clinical resp<>_nse Assessment of relapse Acce_p_tability of treabnent Recording of adverse events Collecting of \,~Sed/ unused trial medication I). Visit 2 (Day6± 1 day) Visit 31 (Day11±2 days) Follow-up visit' (Day 20 or 25, i.e. 14 days 2 to +6 days after treatment completed} x2 x2 x2 x. Visit 3 is only required for those patients who are not rated 'cured' at visit.2 and who therefore have a second course of treatment 2) 3) Only reqllired for those patients who have pathological material present. Follow-u.p visit only required for patients rated ' cured' at end of treatment (visit 2 or visit 3). Patient numbers: Four hundred and sixty-nine patients were recruited and 467 randomi.s ed (exclusion criteria became apparent in two patients). Two patients randomised to Erythroped A were excluded from the safety population (one took no medication the other was lost to follow-up). Therefore the safety population comprised 465 patients.
4 Page 12 of 161 Thirteen patients were excluded from the intention-to-treat efficacy analyses (in addition to the four patients mentioned previously who were excluded from the safety population, nine patients provided no efficacy data). The intentionto-treat population therefore comprised 456 patients. One patient in the Erythroped A group was unevaluable at visit 2. Therefore the analysis was performed on 455 patients in respect of the primary efficacy criterion. A further 19 patients were excluded from the per-protocol population (11 received forbidden medication prior to visit 2, seven had visit 2 efficacy assessments more than three days after their last dose of study medication and one had an incorrect type of infection). The per-protocol population therefore comprised of 437 patients. The bacteriologically evaluable population comprised patients in the perprotocol population in whom a pathogen (Staphylococcus aureus and/or ~ haemolytic streptococci) was isolated at visit 1. There were 137 patients in the bacteriologically evaluable population (70 randomised to Fucidin, 67 randomised to Erythroped A). Efficacy results: The primary criterion of efficacy was the uwestigators' assessment of overall clinical response 'cured' or 'improved' after five days of treatment (visit 2). There was a statistically significant difference between treatments in respect of the primary criterion of efficacy in both the intentionto-treat (p=o.olo, odds ratio 0.38: 95% CI 0.17, 0.80) and per-protocol (p=0.008, odds ratio 0.34: 95% CI 0.14, 0.76) populations in favour of Erythroped A tablets. There was no significant difference (p=0.598, odds ratio 0.73: 95% CI 0.20, 2.40) in the bacteriologically evaluable population. summarised in the table overleaf. Results are
5 Fucidin No. Page 13 of 161 Erythroped" A (\1 No. (\) Odds Ratio 1 (95\ CI) p- va lue No. of patients with overall clinical response at visit 2 of cured or improved INTENTION-TO-TREAT POPULATION (89. 4) 202 (n = 226) (95. 6) 219 (n = ( ) p = PER-PROTOCOL POPULATION 195 (90. 3) (n = (96.41 (n = ( ) p c BACTERIOLOGICALLY EVALUABLE POPULATION 63 (n 62 ( (n = ( p = = 701 (90.01 Odds ratio for the comparison of Fucidin relative to Erythroped A. One patient in the intention-to-treat population was unevaluable at visi t 2. There was a statistically significant difference between treatments with regard to the presence or absence of oedema at visit 2 in the per-protocol population (p=0.038; odds ratio 0.64: 95% CI 0.42, 0.97) in favour of Erythroped A. There were no statistically significant differences between treatments with respect to lesion severity, redness, pain, heat, purulent or serous discharge at visit 2. At the end of treatment there was no statistically significant difference between treatments with respect of the investigators' overall assessment of clinical respons~ in the intention-to-treat (p=0.516, odds ratio 0.84: 95% CI 0.49 to 1.43), per-protocol (p=0.523, odds ratio 0.83: 95% CI 0.47 to 1.46) or ~acteriologlically evaluable (p = 0.560, odds ratio 0.75: 95% CI 0.30 to 1.91) populations. Maintenance of response was monitored 14 days after completion of treatment. Only patients rated as 'cured' at end of tr~atment were eligible to attend the follow-up visit. Of the 374 patients eligible for follow-up (183 Fucidin, 191 Erythroped A), 337 patients attended visit 4 (160 Fucidin of which one patient was. unevaluable, and 177 Erythroped A)~ A relapse was reported in 5.0% of patients in the Fucidin group and 2.8% of patients in the Erythroped A group in the per-protocol population. This represents a high percentage of patients in both treatments where cure was maintained post-treatment (95.0% Fucidin, 97.2% Erythroped A).
6 Page 14 of 161 Bacteriological assessments were performed for all patients at visit 1 and at all subsequent visits where pathological material was still present. Staphylococcus aureus and Only P-haemolytic streptococci were regarded as pathogens. A bacteriological response was assessed (as 'success' or 'failure') in patients who had pathogen(s) present at visit 1. In the bacteriologically evaluable population which comprised 137 patients (70 Fucidin, 67 Erythroped A), the bacteriological response at the end of the.treatment was rated successful in 97.1% of patients on Fucidin tablets and 94.0% of patients on Erythroped A tablets. There was no evidence that Staphylococcus aureus developed resistance to fusidic acid in patients treated with Fucidin tablets. After visit 1, Staphylococcus aureus was isolated from ten patients in the Fucidin group, in all cases the pathogen retained the same sensitivity to fusidic acid throughout the study at whichever visit the pathogen was isolated. There was no evidence that Staphylococcus aureus isolated from patients receiving Erythroped A tablets developed resistance to erythromycin. Safety results: Adverse events were recorded in 69 (30.0%) patients receiving Fucidin tablets and 74 (31.5%) patients receiving Erythroped A tablets. There were 16 withdrawals due to adverse events, ten (4.3%) from the Fucidin group and six (2.5%) from Erythroped A group. Conclusion: At the end of the first five days of treatment (visit 2) there was a statistically significant difference in the overall clinical efficacy between treatments in favour of Erythroped A tablets. Overall the clinical and bacteriological efficacy of Fucidin tablets and Erythroped A tablets was similar with both treatments being highly effective at the end of treatment. Both treatments also demonstrated a low relapse rate and there was no evidence of resistance to fusidic acid developing during or after treatment with Fucidin. Both treatni.ents were well tolerated.
Fusidic acid and erythromycin in the treatment of skin and soft tissue infection: a double blind study Wall A R, Menday A P
Fusidic acid and erythromycin in the treatment of skin and soft tissue infection: a double blind study Wall A R, Menday A P Record Status This is a critical abstract of an economic evaluation that meets
More informationLocation of study report in Regulatory Dossier for authorities
This document has been downloaded from www.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationPFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More information11 August 2000 Page 17 of 181. Subtitle A prospective, multicentre, randomised, double-blind, vehicle-controlled, parallel groupr comparative study.
Study MCO 9604 DE 11 August 2000 Page 17 of 181 2 SYNOPSIS Study Code MCO 9604 DE. Title Addition of Daivonex (calcipotriol) ointment (50 J.Lg!g) to fumaric acid therapy in patients with severe psoriasis
More information13 August Fucidin-H vs. Hydrocortisone in Atopic Dermatitis.
FUH9401DK 13 August 2002 Page 11 of108 2 SYNOPSIS Study code number FUH9401 DKStudy Study title Fucidin-H vs. Hydrocortisone in Atopic Dermatitis. Study Subtitle A comparative study of Fucidin-H cream
More informationPage: Pre-test screening for eligible subjects was performed during the 28 days before the anticipated study start (Day 1).
This document has been downloaded from www.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationPFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More information: Centyr~ 1.25 mg. ~ Centyl 2.5 mg. ~ Renitec(llllO mg. Norvasc 5 mg
CE9401 DK 10 November, 1999 SYNOPSIS Studyc:ode: CE9401 OK Study title: Efficacy and safety of Centyl with potassium chloride (bendroflumethiazide) 1.25 mg and 2.5 mg compared to Renitec (enalapril) 10
More informationPatients who achieved the primary criterion for response i.e.: complete clearance or a reduction
MC 9101 F Study Page3 ABSTRACT Background: Cyclosporin A has been shown to be an effective systemic treatment in severe psoriasis but with the disadvantage of dose-dependent toxic effects particularly
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationLocation of study report in Regulatory Dossier for authorities. Vohune: Page:
This document has been downloaded from W"\vw.leo-pharma.com subject to the tennsofuse state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationClinical Trial Report Synopsis
This document has been do\vnloaded from \v ww.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationObjectives The objectives of the study were to compare the efficacy and safety of three different strengths
MC 392 Study 18 May 1998 PageS ABSTRACT Objectives The objectives of the study were to compare the efficacy and safety of three different strengths of caldpotriol cream (10, 25, 50 f!g/ g) and placebo
More informationEvaluation of Cefuroxime Axetil and Cefadroxil Suspensions
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1992, p. 1614-1618 0066-4804/92/081614-05$02.00/0 Copyright 1992, American Society for Microbiology Vol. 36, No. 8 Evaluation of Cefuroxime Axetil and Suspensions
More informationRochester Patient Safety C. difficile Prevention Collaborative: Long Term Care Antimicrobial Stewardship (funded by NYSDOH)
Rochester Patient Safety C. difficile Prevention Collaborative: Long Term Care Antimicrobial Stewardship (funded by NYSDOH) Clinical Practice Guideline* for the Diagnosis and Management of Acute Bacterial
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationL. Montero. Carrera 16# , Consultorio 303, Santafe de Bogotd, D.C., Colombia
Journal of Antimicrobial Chemotherapy (1996) 37, Suppl. C, 125-131 A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationMC 590 ABSTRACT. PageS
This docwnent has OOen dov,nloaded from 'W'W'\VJ eo-pharma.c-om subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or
More informationStaph infection groin pictures
Staph infection groin pictures Search TheBody.com fills you in on the topic, staph infections on the groin, with a wealth of fact sheets, expert advice, community perspective, the latest news/research.
More informationLymphoedema in Wales - Mixing Oedema and Infection
Lymphoedema in Wales - Mixing Oedema and Infection Melanie Thomas Karen Morgan 5/6/2014 1 National Clinical Lead Lymphoedema National Education & Research Lymphoedema Specialist Lymphoedema: Photographs
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fucidin 20 mg/g ointment 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of ointment contains 20 mg sodium fusidate For a full list
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 CUBICIN 350 mg (daptomycin), powder for perfusion solution Box of 1 bottle (CIP code: 567 219-3) CUBICIN
More informationTOUGH ON IMPETIGO GENTLE ON THE1 PATIENT. Demonstrated efficacy and safety1. New treatment option now available!
New treatment option now available! TOUGH ON IMPETIGO GENTLE ON THE1 PATIENT Demonstrated efficacy and safety1 Home Efficacy Safety Convenience (ozenoxacin) is indicated for the topical treatment of impetigo
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information2 SYNOPSIS. Study code : MC 9308 FR.
MC9308 FR Study 19 December 2000 Page 15 of142 2 SYNOPSIS Study code : MC 9308 FR. Title: A comparative study of calcipotriol ointment in combination with narrow-band UVB (TL-01) phototherapy and placebo
More informationProtocol Number: BV-2005/01. OM Pharma OM-85
Page 3 SYNOPSIS Protocol Number: Name of Finished Product: Broncho-Vaxom (Broncho-Munal ) Title: Double-Blind, Placebo-Controlled, Randomised Clinical Study of Broncho-Vaxom in Children Suffering from
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Fucidin 20mg/g Cream Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram of cream contains 20mg fusidic acid. Excipients with known effect:
More informationJAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections
Journal of Antimicrobial Chemotherapy (1998) 41, Suppl. B, 69 73 JAC Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections G. Tatsis*, G.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationS t a p h i n f e c t i o g r o i n p i c t u r e s
S t a p h i n f e c t i o g r o i n p i c t u r e s When someone is under an infection either in any area of the body or in the groin to be specific, the lymph nodes will swell up. Lymph nodes are located
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationDrug Class Review on Macrolides
Drug Class Review on Macrolides Preliminary Scan Report 5 July 2014 Last Report: Original August 2006 The purpose of reports is to make available information regarding the comparative clinical effectiveness
More informationALTARGO TM Retapamulin. QUALITATIVE AND QUANTITATIVE COMPOSITION Retapamulin 10 mg per gram (1% w/w)
ALTARGO TM Retapamulin QUALITATIVE AND QUANTITATIVE COMPOSITION Retapamulin 10 mg per gram (1% w/w) PHARMACEUTICAL FORM Ointment. CLINICAL PARTICULARS Indications ALTARGO (retapamulin) 1% ointment is indicated
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMD, Haematology and Thromboembolism, St. Joseph's Hospital,
This document has been dov.'llloaded from W'\V\vJeo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationLocation of study report in Regulatory Dossier for authorities
This document has been downloaded from www.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More information(NATO STANAG 2122, CENTO STANAG 2122, SEATO STANAG 2122)
(NATO STANAG 2122, CENTO STANAG 2122, SEATO STANAG 2122) Bacteria Bacteria are microscopic, single-celled forms of plant life, containing no chlorophyll. They live on the skin, on the surface of the stratum
More informationMRSA: A TEAM APPROACH
Eric Bosley, MD Laura Stadler, MD John MD J h Draus, D MRSA: A TEAM APPROACH PART I: OUTPATIENT ISSUES AND MANAGEMENT NOT REQUIRING I&D OR HOSPITALIZATION Eric L. Bosley, MD, FAAP Pediatric Associates,
More informationPATCH Analysis Plan v1.2.doc Prophylactic Antibiotics for the Treatment of Cellulitis at Home: PATCH Analysis Plan for PATCH I and PATCH II Authors: Angela Crook, Andrew Nunn, James Mason and Kim Thomas,
More informationStaph Infections. including MRSA
Staph Infections including MRSA What is a Staph infection? STAPH Staphylococcus aureus, often referred to simply as staph, are bacteria commonly carried on the skin or in the nose of healthy people. SYMPTOMS
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
1 SYNOPSIS (CR002878) Title of Study: The effect of on vasomotor symptoms in healthy postmenopausal women: a double-blind placebo controlled pilot study Investigators: Multiple, see Section 4, Investigators
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex sodium (ABT-711) Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationClinical Trial Report Synopsis. Patient insights following use of LEO aerosol foam and Daivobet gel in subjects with psoriasis vulgaris
This document has been downloaded from W\vw.leo-pharma.com subject to the ten:n.s of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationClinical Study Report Synopsis
This document has been dovmloaded from www.leo-pharma.c.om subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationOBSTETRICS & GYNECOLOGY
DECEMBER 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Migraine Headache
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClarithromycin versus penicillin in the treatment of streptococcal pharyngitis
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. A, 67-74 Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis Joseph H. Levenstein* South Africa Academy of Family Practice,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT Fusidic Acid 2% Cream SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 % cream. Each gram contains 20 mg fusidic acid. Excipient(s) with
More informationA French, multicentre, placebo-controlled, randomised, double-blind,
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Blum CA, Nigro N, Briel M, et al. Adjunct prednisone
More informationpaliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd
Re-Submission paliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) SMC No. (713/11) Janssen-Cilag Ltd 07 October 2011 The Scottish Medicines Consortium
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: TOPMAT-MIG-303 EudraCT No.: 2005-000321-29 Title of Study: A double-blind, randomised, placebo-controlled, multicentre study to investigate the efficacy and tolerability of in prolonged
More informationroflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationScottish Medicines Consortium
Scottish Medicines Consortium cetuximab 2mg/ml intravenous infusion (Erbitux ) (279/06) MerckKGaA No 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationScottish Medicines Consortium
Scottish Medicines Consortium epoetin theta, 1,000 IU/0.5mL, 2,000 IU/0.5mL, 3,000 IU/0.5mL, 4,000 IU/0.5mL, 5,000 IU/0.5mL, 10,000 IU/1mL, 20,000 IU/1mL, 30,000 IU/1mL solution for injection in pre filled
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More informationChapter 4 Inflammation and Infection
Chapter 4 Inflammation and Infection Defense Mechanisms Three lines of defense protect the body against foreign invasion: Physical or surface barriers Inflammation Immune response Inflammation Non-specific
More informationCellulitis: a practical guide
Cellulitis: a practical guide Dr John Day Consultant in Infectious Diseases & General Medicine Southend University Hospital NHS Foundation Trust 77 yr old retired civil servant A&E presentation c/o rigors
More informationScottish Medicines Consortium
Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium
More informationClinical Trial Study Synopsis
Clinical Trial Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency
More informationvaccination. Children enrolled in these clusters between 6 weeks and 6 months of age received a 2-dose primary vaccination schedule.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPhenoxymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of /Mactamase activity in saliva
Journal of Antimicrobial Chemotherapy (1996) 7, 1-18 Phexymethyl penicillin versus co-amoxiclav in the treatment of acute streptococcal pharyngitis, and the role of /Mactamase activity in saliva R. S.
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationBevacizumab for the treatment of recurrent advanced ovarian cancer
Bevacizumab for the treatment of recurrent advanced ovarian cancer ERRATUM This report was commissioned by the NIHR HTA Programme as project number 11/40 Page 2 This document contains errata in respect
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationPPP 1. Continuation, modification, and discontinuation of a medication
PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The
More informationGSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and nonapproved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinialTrials.gov Identifier: Sponsor/company: sanofi-aventis
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationdronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd
dronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd 6 August 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationScottish Medicines Consortium
Scottish Medicines Consortium pregabalin, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules (Lyrica ) No. (389/07) Pfizer Limited 6 July 2007 The Scottish Medicines Consortium has completed
More informationStudy No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information2. SYNOPSIS Name of Sponsor/Company:
in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,
More informationA randomised, double-blind, parallel group, multicentre study to compare the tolerability, safety, and efficacy of oxycodone with morphine in
A randomised, double-blind, parallel group, multicentre study to compare the tolerability, safety, and efficacy of oxycodone with morphine in patients using i.v. patient-controlled analgesia (PCA) for
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-6511694:4.0 Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development Name of Finished Product Name of Active Ingredient Protocol
More informationSurveillance report Published: 30 January 2017 nice.org.uk
Surveillance report 2017 Surgical site infections: prevention ention and treatment (2008) NICE guideline Surveillance report Published: 30 January 2017 nice.org.uk NICE 2017. All rights reserved. Subject
More informationThis was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationScottish Medicines Consortium
Scottish Medicines Consortium infliximab 100mg powder for intravenous infusion (Remicade ) No. (364/07) Schering-Plough UK Ltd 6 April 2007 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationAbscess. A abscess is a localized collection of pus in the skin and may occur on any skin surface and be formed in any part of body.
Abscess A abscess is a localized collection of pus in the skin and may occur on any skin surface and be formed in any part of body. Ethyology Bacteria causing cutaneous abscesses are typically indigenous
More informationD. A. Leigh and G. Joy. Department of Microbiology, Wycombe General Hospital, High Wycombe, Bucks HP11 2TT, UK
Journal of Antimicrobial Chemotherapy (13) 31, 0-17 Treatment of familial staphylococcal infection comparison of mnpirocin nasal ointment and chlorhexidine/neomycin (aseptin) cream in eradication of nasal
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 CARDENSIEL 1.25 mg, film-coated tablet B/30 (CIP code: 352 968-1) CARDENSIEL 2.5 mg, film-coated tablet
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationStatistical Analysis Plan
Effectiveness of nutritional supplementation (RUTF and multi micronutrient) in preventing malnutrition in children 6-59 months with infection (malaria, pneumonia, diarrhoea), a randomized controlled trial
More informationUsing the BNF. CWFS F1 Programme Safe Prescribing Module
Using the BNF CWFS F1 Programme Safe Prescribing Module Know Your BNF Guidance on prescribing - Controlled drugs and dependence - Prescribing in palliative care/elderly/children Emergency treatment of
More informationClincialTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClincialTrials.gov
More informationPATIENT INFORMATION LEAFLET SIMVACOR RANGE
SCHEDULING STATUS: S4 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: SIMVACOR 10 mg (Each film coated tablet contains simvastatin 10 mg) SIMVACOR 20 mg (Each film coated tablet contains simvastatin
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis AbbVie Inc. Name of Study Drug: Humira Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Study:
More informationDiagnosing wound infection - a clinical challenge
Diagnosing wound infection - a clinical challenge Keith F Cutting Merimbula, 5 th November 2010 Wound infection microbial load immune system microbial load + + + immune system infection host response Diagnosing
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationScottish Medicines Consortium
Scottish Medicines Consortium sorafenib 200mg tablets (Nexavar ) (No. 321/06) Bayer Plc 6 October 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationHealthy Skin and Skin Infections. Prepared by the Midland Region Child Health Action Group Skin Subgroup
Healthy Skin and Skin Infections Prepared by the Midland Region Child Health Action Group Skin Subgroup Objectives of this presentation This presentation will: Support health professional knowledge development
More information